The Top 10 Biopharmaceutical M&A deals of 2023.
Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation jcm9144@gmail.com
SPECIAL REPORT 24.03
The Top 10 Biopharmaceutical M&A deals of 2023.
Every beginning of the year, Fierce Pharma issues a series of valuable reports addressing economic features in the biopharmaceutical industry. The one mentioned today relates to Mergers and Acquisitions (M&A) dealmaking for 2023 and is published under:
The top 10 biopharma M&A deals of 2023 | Fierce Pharma
We wish to focus on a few topics of interest to the field.
The value of the 10 top M&A deals of 2023 came to $115.8 billion far above the 2022 sum of $65 billion.
Four out of the ten major deals were announced in the month of December a strong indicator of renewed M&A activity at year end.
In 2023, the largest acquisition was the one of Seagen by Pfizer at $43 billion far below the ones of Bristol-Myers Squibb’s of Celgene for $74 billion in 2019 or AbbVie’s $63 billion buyout of Allergan in 2020.
.The field of Antibody-drugs conjugates (ADCs) was the star of the year which is reflected by the take over of Seagen by Pfizer, the acquisition of Immunogen by AbbVie for $10.1 billion and the strategic collaboration between Merck and Daiichi Sankyo’s technology for a potential consideration of up to $22 billion.
The field of Neuroscience also makes the scene with BMS’ Karuna buy for $14 billion, AbbVie’s acquisition of Cerevel Therapeutics for $8.7 billion and Biogen takeover of Reata for $7.3 billion.
Bristol-Myers Squibb made three major agreements collectively worth $23.9 billion.
Roche ‘s acquisition of Telavant for $7.1 billion was the only major deal from a European based company in 2023. This has already dramatically changed with the recent announcements in 2024 of GlaxoSmithKline’s agreement to acquire Aiolos Bio for $1.4 billion, Sanofi’s acquisition of Inhibrx for $2.2 billion, Novartis buy of Morphosys for $2.8 billion and Novo Holdings take over of Catalent, a major CDMO, for $16.5 billion.
Top 10 M&A Deals
- Pfizer and Seagen (ADC platform). Deal value: $43 billion.
- Bristol-Myers Squibb and Karuna Therapeutics (KarTX a first in class M1/M4 muscarinic receptor agonist for the treatment of schizophrenia). Deal value: $14 billion.
- Merck and Prometheus Biosciences (PRA-023 a candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions). Deal value: $10.8 billion.
- AbbVie and Immunogen (ADC platform). Deal value: $10.1 billion.
- AbbVie and Cerevel Therapeutics (Emraclidine, a muscarinic M4 allosteric modulator for the treatment of schizophrenia and Alzheimer’s psychosis). Deal value of 8.7 billion.
- Biogen and Reata Pharmaceuticals (Skyclarys for the treatment of neurological inherited Friedreich’s ataxia). Deal value: $7.3 billion.
- Roche and Telavant Holdings (RVT-3101, a TLA1 antibody for the treatment of inflammatory bowel disease and Ulcerative colitis. Deal value: 7.1 billion.
- Astellas and Iveric Bio (Izervay for the treatment of geographic atrophy (GA) an intraocular inflammation). Deal value: $5.9 billion.
- Bristol-Myers Squibb and Mirati Therapeutics (Krazati, a KRAS G12C-mutated non small cell lung cancer treatment). Deal value: $4.8 billion.
- Bristol-Myers Squibb and RayzeBio (Radiopharmaceutical platform for treatments of gastroenteropancreatic tumors, small cell lung cancer and hepatocellular carcinoma). Deal Value: $4.1 billion.
Paris, February 6, 2024
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.
Last News
- Note de réflexion de fin d’année
- EMA re-examines its opinion and approves Leqembi for the treatment of Alzheimer’s disease
- Le déclassement de la France
Events
News archives
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012